52P MUC1 targeted immunotherapy with an oncolytic adenovirus coding for a bispecific T cell engager. (December 2022) - Basnet, S.; Santos, J.M.; Quixabeira, D.C.A.; Clubb, J.; Grönberg-Vähä-Koskela, S.; Pakola, S.; Kudling, T.; Heiniö, C.; Havunen, R.; Cervera-Carrascon, V.; Sorsa, S.; Anttila, M.; et al.